

Lenvatinib as a promising treatment option for unresectable hurthle cell carcinoma: a case report.

Parth S. Shirode

Apollo Hospitals, Navi Mumbai, India.

In this case report, we highlight the importance of Lenvatinib, a Tyrosine Kinase Inhibitor (TKI), as a management strategy for technically-unresectable Differentiated Thyroid Carcinoma (DTC). A 37-year-old gentleman presented with a locally advanced and widely metastasized case of large Hurthle cell carcinoma (HCC) encasing the left carotid sheath and the left recurrent laryngeal nerve. Fine needle aspiration cytology (FNAC) and very high (300,000 ng/ml) levels of serum thyroglobulin (Sr. TG) were suggestive of HCC. The patient received oral Lenvatinib 20 mg once daily as part of the treatment, and the response profile was assessed. The treatment protocol for thyroid cancers of any size that invade local structures is total thyroidectomy with extended resection. But surgical management is challenging if the tumor is locally advanced and invades major neck structures with an increased risk of recurrence. TKIs are used in the case of advanced disease, especially in unresectable, radio-iodine refractory, and metastatic status. Lenvatinib, a TKI, used as the first line of treatment, plays a key role in improving prognosis and survival rates among patients. The median progression-free survival (PFS) with Lenvatinib is 18.3 months. Whereas, in this patient, the treatment clinically translated into a good response in a high disease burden scenario and showed positive results with a PFS of 30 months and a reduction in the size of the tumor, along with an overall improvement of well-being.

Keywords: Tyrosine Kinase Inhibitor, Thyroid Carcinoma, and Hurthle cell carcinoma.

Biography

Dr. Parth S. Shirode is a recent Medical Graduate (M.B.B.S.) from Terna Medical College, Hospital and Research Centre, Navi Mumbai, IND. He has had experience working as a Resident Medical Officer at Apollo Hospitals, Navi Mumbai, IND. There, he witnessed a rare case that he studied and successfully published under the guidance of Dr. Anil D'cruz of Head and Neck Surgery. Parth is a research enthusiast who is determined towards addressing the upcoming issues concerning the field of pediatrics through his articles. He aspires to be a dedicated pediatrician in the United States and is currently preparing for USMLE. He aims to contribute to the field of Medicine through his exceptional professional and clinical research skills in the years to come.

Received: June 01, 2023; **Accepted:** June 02, 2023; **Published:** September 18, 2023
